Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Gastric cancer is a very common gastrointestinal malignancy. Since the disease is often asymptomatic in its early stage, it is often diagnosed in its late stage. In this study, our objective was to evaluate the efficacy and safety of combination chemotherapy regimens containing taxanes in the first-line treatment of advanced gastric cancer (AGC). We searched published randomized controlled trials (RCTs) to compare the effect of taxanes combined with basic chemotherapy and chemotherapy without taxanes on AGC. The extracted data are the number of people who achieved the objective response rate (ORR) and disease control rate (DCR), as well as the hazard ratio (HR) of progression-free survival (PFS) and overall survival (OS) including their 95% confidence intervals (95% CI). Six RCTs involving 2263 patients were included. Compared with chemotherapy without taxanes, patients receiving taxanes combined with basic chemotherapy had significantly longer PFS (HR 0.73, 95% CI 0.61–0.88, p = 0.001) and significantly longer OS (HR 0.80, 95% CI 0.69–0.93, p = 0.003); significantly better ORR (RR 1.34, 95% CI 1.15–1.57, p = 0.0001) and significantly better DCR (RR 1.20, 95% CI 1.08–1.33, p = 0.001). However, in patients treated with taxanes combined with basic chemotherapy, diarrhea, leukopenia and neutropenia were significantly increased (p < 0.05). In summary, taxanes combined with basic chemotherapy are superior to chemotherapy without taxanes in first-line treatment of AGC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Data availability

The data contained in this article can be applied.

References

  1. Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535-547.

    Article  PubMed  Google Scholar 

  2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–43.

    Article  CAS  PubMed  Google Scholar 

  3. Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008;13(7):794–806.

    Article  CAS  PubMed  Google Scholar 

  4. Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res. 2003;23(5b):4219–22.

    CAS  PubMed  Google Scholar 

  5. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72(1):37–41.

    Article  CAS  PubMed  Google Scholar 

  6. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(3):587–91.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999;22(6):580–6.

    Article  CAS  PubMed  Google Scholar 

  8. Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001;12(1):47–51.

    Article  CAS  PubMed  Google Scholar 

  9. Ajani JA, Baker J, Pisters PW, et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002;16(5 Suppl 5):16–8.

    PubMed  Google Scholar 

  10. Slingerland M, Guchelaar HJ, Rosing H, et al. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. Clin Ther. 2013;35(12):1946–54.

    Article  CAS  PubMed  Google Scholar 

  11. Vergote I, Scambia G, O’Malley DM, et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(6):862–76.

    Article  CAS  PubMed  Google Scholar 

  12. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–37.

    Article  CAS  PubMed  Google Scholar 

  13. Xia RL, Lu Y, Zhu LN, Zhang SF, Zhao FK, Fu CY. Different regulatory pathways are involved in the proliferative inhibition of two types of leukemia cell lines induced by paclitaxel. Oncol Rep. 2013;30(4):1853–9.

    Article  CAS  PubMed  Google Scholar 

  14. Li G, Xu D, Sun J, Zhao S, Zheng D. Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway. Adv Clin Exp Med. 2020;29(11):1337–45.

    Article  PubMed  Google Scholar 

  15. Jiang X, Zhang B, Zhou Z, et al. Enhancement of radiotherapy efficacy by pleiotropic liposomes encapsulated paclitaxel and perfluorotributylamine. Drug Deliv. 2017;24(1):1419–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998;21(4):416–9.

    Article  CAS  PubMed  Google Scholar 

  17. Yamada Y, Shirao K, Ohtsu A, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12(8):1133–7.

    Article  CAS  PubMed  Google Scholar 

  18. Fujitani K, Narahara H, Takiuchi H, et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology. 2005;69(5):414–20.

    Article  CAS  PubMed  Google Scholar 

  19. Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–10.

    Article  PubMed  Google Scholar 

  20. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.

    Article  PubMed  Google Scholar 

  21. Lim JY, Cho JY, Paik YH, et al. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. Oncology. 2007;73(1–2):2–8.

    Article  CAS  PubMed  Google Scholar 

  22. Yamaguchi K, Shimamura T, Hyodo I, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer. 2006;94(12):1803–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006;12(11 Pt 1):3402–7.

    Article  CAS  PubMed  Google Scholar 

  24. Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140(2):319–28.

    Article  CAS  PubMed  Google Scholar 

  25. Tsuburaya A, Nagata N, Cho H, et al. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 2013;71(5):1309–14.

    Article  CAS  PubMed  Google Scholar 

  26. Shinkai M, Imano M, Chiba Y, et al. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. J Surg Oncol. 2019;119(1):56–63.

    Article  CAS  PubMed  Google Scholar 

  27. Crown J, O’Leary M. The taxanes: an update. Lancet. 2000;355(9210):1176–8.

    Article  CAS  PubMed  Google Scholar 

  28. Nishina T, Boku N, Gotoh M, et al. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Gastric Cancer. 2016;19(3):902–10.

    Article  CAS  PubMed  Google Scholar 

  29. Rosenberg AJ, Rademaker A, Hochster HS, et al. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in metastatic and unresectable gastric/gastroesophageal junction adenocarcinoma: a phase II study with long-term follow-up. Oncologist. 2019;24(8):1039-e642.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018;36(19):1922–9.

    Article  CAS  PubMed  Google Scholar 

  31. Jardim DL, Rodrigues CA, et al. Oxaliplatin-related thrombocytopenia. Ann Oncol. 2012;23(8):1937–42.

    Article  CAS  PubMed  Google Scholar 

  32. Erdem GU, Dogan M, Demirci NS, et al. Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther. 2016;12(2):509–14.

    Article  CAS  PubMed  Google Scholar 

  33. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003;30(4 Suppl 15):5–13.

    Article  CAS  PubMed  Google Scholar 

  34. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29(5 Suppl 15):11–20.

    Article  CAS  PubMed  Google Scholar 

  35. Chen MH, May BH, Zhou IW, et al. Integrative medicine for relief of nausea and vomiting in the treatment of colorectal cancer using oxaliplatin-based chemotherapy: a systematic review and meta-analysis. Phytother Res. 2016;30(5):741–53.

    Article  CAS  PubMed  Google Scholar 

  36. Hamaguchi T. A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT). Clinical Trial Registration Number: UMIN000008866. https://meetings.asco.org/abstracts-presentations/204531

  37. van Dooijeweert C, van der Wall E, Baas IO. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles. Neth J Med. 2019;77(9):310–6.

    PubMed  Google Scholar 

  38. Sato S, Kunisaki C, Tanaka Y, et al. A phase II study of tri-weekly low-dose nab-paclitaxel chemotherapy for patients with advanced gastric cancer. Anticancer Res. 2018;38(12):6911–7.

    Article  PubMed  Google Scholar 

  39. Sakai H, Sagara A, Matsumoto K, et al. Neutrophil recruitment is critical for 5-fluorouracil-induced diarrhea and the decrease in aquaporins in the colon. Pharmacol Res. 2014;87:71–9.

    Article  CAS  PubMed  Google Scholar 

  40. Tan H, Hu J, Liu S. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 2019;47(1):268–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

This work was supported by Beijing Natural Science Foundation of China (No.7212168).

Author information

Author notes

  1. Xiaoting Ma and Yujian Zhang contributed equally to this work.

Authors and Affiliations

  1. Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Xicheng District, Beijing, 100050, China

    Xiaoting Ma, Yujian Zhang, Cong Wang & Jing Yu

Authors
  1. Xiaoting Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yujian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XTM and JY contributed to the conception and design this study. XTM and YJZ carried out the development of the methodology. CW analyzed and interpreted the data. XTM and YJZ wrote the manuscript and approved the final submission of the study. JY provided funding. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jing Yu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interests.

Ethical approval and consent to participate

None.

Consent for publication

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, X., Zhang, Y., Wang, C. et al. Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer. Clin Exp Med 23, 381–396 (2023). https://doi.org/10.1007/s10238-022-00824-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-022-00824-1

Keywords

Search

Navigation